A mid-size, top 5 European pharmaceutical company engaged PRA in a global Phase III study in 20 countries on patients with advanced breast cancer previously treated with or resistant to airmaximus an anthracycline and who are taxane resistant. By identifying optimal sites in in Russia, Ukraine, Belarus, and Estonia, PRA recruited 318 patients at 25 sites, compared to 450+ patients at 150 sites in Rest of World (ROW).
Explore related content and topics
Blog
Kids with Cancer: A Survivor Shares Her Story
Read Story
Case Study
PRA Successfully Rescues Phase II Hematology Study
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to…
View Resource
Webinar
The Challenges of Patient Recruitment in Oncology Trials - Part 3
A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical…
View Resource
View all related content and resources for Oncology
Explore Insights